Certara (CERT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$421.7M

Revenue (quarter)

$93.3M

Revenue growth (year over year)

+0.99%

Gross profit (trailing twelve months)

$259.8M

Gross margin

61.61%

Net income (trailing twelve months)

−$68.4M

Net income (quarter)

−$55.3M

Net income growth (year over year)

−2708.43%

Net margin

−16.22%

Return on equity

−6.72%

EPS (trailing twelve months)

−$0.44

Book value per share

$6.34

P/E (trailing twelve months)

—

Price to book

1.48

Debt to assets

30.95%

Payout ratio

—

Dividend yield

—

Company profile

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

• Is Certara (CERT) profitable?

  No. Certara reported a net loss of $68.4M over the trailing twelve months.

• How much revenue does Certara (CERT) make?

  Certara generated $421.7M in revenue over the trailing twelve months, up 0.99% year over year.

• How do I buy stock in Certara (CERT)?

  CERT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.